Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Clinical trial NCT02115295 · RECRUITING

Trial details

NCT number: NCT02115295
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Biphenotypic Leukemia Acute Myeloid Leukemia Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Blasts 10 Percent or More of Bone Marrow Nucleated Cells Blasts 10 Percent or More of Peripheral Blood White Cells de Novo Myelodysplastic Syndrome Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Acute Myeloid Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Start date: 2014-05-19
Primary completion: 2030-05-31
Enrollment: 508

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.